SCHEMBL2583674

SCHEMBL2583674

CC(OC(=O)OC(C)c1ccccc1Nc1ccccn1)c1ccccc1Nc1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPK10 P53779 1/20 0.51
GFER P55789 1/20 0.51
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.41
LMNA P02545 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
GRM5 P41594 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094163 0.79 MEN1 (0.66) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL3279571 0.71 MEN1 (1.00) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL29394920 0.71 KDM4E (0.60) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL3787394 0.69 ALDH1A1 (0.33) KMT2ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL5246669 0.69 NPC1 (0.56) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL5771649 0.69 MAPK10 (0.70) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL29395312 0.68 MEN1 (0.63) MEN1KMT2AMAPK10GFERALDH1A1
SCHEMBL4241669 0.68 MEN1 (0.63) MEN1KMT2AMAPK10GFERALDH1A1
SCHEMBL3649101 0.68 RXFP1 (0.50) MEN1KMT2AMAPK10GFERNPC1
Cadaverine Tartrate SCHEMBL28285807 0.67 RAB9A (0.53) MEN1KMT2AMAPK10GFERNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4138923-A1 DRUG ANTIBODY CONJUGATES Pharma Mar, S.A. (ES) 2023-03-01 EP disclosed
WO-2021214126-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2021-10-28 WO disclosed
EP-3615544-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2020-03-04 EP disclosed
WO-2018197663-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2018-11-01 WO disclosed
US-20110269957-A1 SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2231695-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2010-09-29 EP disclosed
WO-2009077401-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-06-25 WO disclosed
EP-2032551-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-03-11 EP disclosed
WO-2007144423-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269957-A1 SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MEN1 1622/4885KMT2A 4186/4885MAPK10 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.